Humana surges: Barclays bets big on Medicare star ratings rebound

On Friday, Humana Inc. (NYSE:HUM) shares experienced a significant surge, climbing 6% following a noteworthy upgrade from Barclays. The health insurer was elevated from an "equal-weight" rating to "overweight," signaling greater confidence in its future performance, particularly in relation to the upcoming Medicare Star ratings release.

Barclays analyst Andrew Mok made the upgrade, citing his increased conviction in the company's prospects ahead of the Medicare Star ratings catalyst expected around October 8. Mok's decision to upgrade was based on his belief that Humana would secure several contracts and transition them to a bonus status, with H5216 being the most critical component.

H5216, which covers 2.4 million lives, is considered a vital piece of the company's long-term 2028 EPS target, valued at approximately $1.5 billion in EBIT and $9 in EPS. Mok raised the probability of H5216 receiving an upgrade to 75%, emphasizing that Humana enters the 2028 ratings cycle in a stronger position compared to a year prior. Barclays also raised its price target for Humana to $515, up from the previous $407.